Breakthrough Pain In Opioid Tolerant Patients — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for breakthrough pain in opioid tolerant patients. 68 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
68
Active US patents
51/100
Avg vulnerability
—
Annual revenue covered

Originators in Breakthrough Pain In Opioid Tolerant Patients

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Johnson & Johnson (Janssen Pharmaceutica) 68 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating breakthrough pain in opioid tolerant patients. Each bar = one year. Y-axis scaled to peak year (54 patents).

54
27
14
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Duragesic
fentanyl
 Johnson & Johnson (Janssen Pharmaceutica) 68 51 — 2027-01-25

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
8835460 Duragesic method of use 68 2027-01-25
9289387 Duragesic method of use 63 2027-01-25
9642797 Duragesic method of use 63 2027-01-25
9289387 Duragesic method of use 63 2027-01-25

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
8486972 Duragesic formulation 36 2030-04-27
10610523 Duragesic formulation 43 2027-01-25
10610523 Duragesic formulation 43 2027-01-25
10016403 Duragesic formulation 43 2027-01-25

Related